Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry.
Menter A, Thaçi D, Wu JJ, Abramovits W, Kerdel F, Arikan D, Guo D, Ganguli A, Bereswill M, Camez A, Valdecantos WC. Menter A, et al. Among authors: thaci d. Dermatol Ther (Heidelb). 2017 Sep;7(3):365-381. doi: 10.1007/s13555-017-0198-x. Epub 2017 Aug 16. Dermatol Ther (Heidelb). 2017. PMID: 28815476 Free PMC article.
Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice.
Maul JT, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, Drach M, Blome C, Boehncke WH, Thaci D, Reich K, von Kiedrowski R, Körber A, Yawalkar N, Mainetti C, Laffitte E, Streit M, Rustenbach S, Conrad C, Borradori L, Gilliet M, Cozzio A, Itin P, Häusermann P, French LE, Radtke MA, Augustin M. Maul JT, et al. Among authors: thaci d. J Eur Acad Dermatol Venereol. 2019 Apr;33(4):700-708. doi: 10.1111/jdv.15324. Epub 2019 Jan 15. J Eur Acad Dermatol Venereol. 2019. PMID: 30388318 Free article.
Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
Thaçi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A, Eyerich K. Thaçi D, et al. Br J Dermatol. 2020 Aug;183(2):265-275. doi: 10.1111/bjd.18696. Epub 2020 Jan 20. Br J Dermatol. 2020. PMID: 31705526 Clinical Trial.
Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study.
Maul JT, Augustin M, Sorbe C, Conrad C, Anzengruber F, Mrowietz U, Reich K, French LE, Radtke M, Häusermann P, Maul LV, Boehncke WH, Thaçi D, Navarini AA. Maul JT, et al. Among authors: thaci d. Br J Dermatol. 2021 Dec;185(6):1160-1168. doi: 10.1111/bjd.20387. Epub 2021 Jun 22. Br J Dermatol. 2021. PMID: 33837519
Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials.
Thaçi D, Jullien D, Egeberg A, Carrascosa JM, Wu JJ, Pau-Charles I, Gisondi P. Thaçi D, et al. J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e709-e711. doi: 10.1111/jdv.17427. Epub 2021 Jul 14. J Eur Acad Dermatol Venereol. 2021. PMID: 34058035 Clinical Trial. No abstract available.
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB. Thaçi D, et al. Dermatol Ther (Heidelb). 2022 Feb;12(2):495-510. doi: 10.1007/s13555-021-00649-y. Epub 2022 Jan 13. Dermatol Ther (Heidelb). 2022. PMID: 35025062 Free PMC article.
324 results